Apalutamide as a new option for postponing metastatic disease in hormone-resistant patients with biochemical recurrence in prostate cancer Case report

Main Article Content

Bartosz Dąbek

Abstract

Treatment of non-metastatic castration-resistant prostate cancer is a radically new option for cancer patients. Novel anti-hormonal therapy not only improves metastasis free survival but overall survival times and positively impacts quality of life. This case shows how apalutamide lowered tPSA level and postponed metastatic disease.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Dąbek B. Apalutamide as a new option for postponing metastatic disease in hormone-resistant patients with biochemical recurrence in prostate cancer. OncoReview [Internet]. 2023Apr.1 [cited 2024Jul.18];13(1(49):24-6. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/2790
Section
SUPPORTIVE CARE IN ONCOLOGY

References

1. Siegel RL, Miller KD, Wagle NS et al. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1): 17-48. http://doi.org/10.3322/caac.21763.
2. Smith MR, Saad F, Chowdhury S et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018; 378: 1408-18. http://doi.org/10.1056/NEJMoa1715546.
3. Hussain M, Fizazi K, Saad F et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018; 378: 2465-74.
4. Fizazi K, Shore N, Tammela TL et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2019; 380: 1235-46. http://doi.org/10.1056/NEJMoa1815671.
5. Hofman MS, Lawrentschuk N, Francis RJ et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative- intent surgery or radiotherapy (proPSMA ): A prospective, randomised, multicentre study. Lancet. 2020; 395: 1208-16. http://doi.org/10.1016/S0140-6736(20)30314-7.
6. Afshar-Oromieh A, Holland-Letz T, Giesel FL et al. Diagnostic performance of (68)Ga-PSMA -11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: Evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017; 44: 1258-68. http://doi.org/10.1007/s00259-017-3711-7.